StockSelector.com
  Research, Select, & Monitor Monday, July 16, 2018 8:06:31 PM ET  
Trade Ideas The Market Industries Stocks Portfolio

 
Ticker Lookup
Melinta Therapeutics, Inc.$6.05($.40)(6.20%)

  Quote | Chart | Valuations | Sentiment | Industry | News | Earnings | Analysts | More...

Your Target?

Melinta Therapeutics, Inc. has an overall rank of 6846 out of 7006 stocks based on 5 positive rankings and 10 negative rankings.

Positive Rankings
Estimated Revenue Growth
Melinta Therapeutics rank is 121
Up Ratings Revision
During the past month, the average analyst's rating or recommendation has increased. Among companies that have been upgraded within the past month, Melinta Therapeutics is ranked 228.
Low/Rising MACD
The MACD remains negative, but is rising... suggesting a possible near-term correction. Of companies with a negative, but rising MACD, Melinta Therapeutics is ranked 488.
Up EPS Surprise
Melinta Therapeutics beat the consensus earnings estimate when it last reported quarterly earnings.
Debt-to-Equity
Melinta Therapeutics rank is 2296
Negative Rankings
High vPut/Call
Melinta Therapeutics has a high Put/Call ratio of 5.00 on active options expiring within the next 90 days. A high put-to-call ratio indicates there are more bearish investors than bullish investors for the stock. Among companies with a high Put/Call Ratio, Melinta Therapeutics is ranked 122.
90 Day Loss
Melinta Therapeutics rank is 173
Negative Net Margin
Melinta Therapeutics rank is 361
Negative ROE
Melinta Therapeutics rank is 406
Negative Cash Growth
Melinta Therapeutics rank is 562
Negative ROA
Melinta Therapeutics rank is 633
High Put/Call
Melinta Therapeutics has a high Put/Call ratio of 0.73 on all open interest of options expiring in the next 90 days. A high put-to-call ratio indicates there are more bearish investors than bullish investors for the stock. Among companies with a high Put/Call Ratio, Melinta Therapeutics is ranked 691.
Price-to-Sales
Melinta Therapeutics rank is 941
10 Day Loss
Melinta Therapeutics rank is 1056
Price-to-Book
Melinta Therapeutics rank is 1843







Register |  Password |  Feedback |  Copyright |  Usage Agreement |  Privacy Policy |  Advertising |  About Us |  Contact Us |  FAQ 

Past performance is not indicative of future results

StockSelector.com, the StockSelector.com logo, and News Selects are trademarks of StockSelector.com.
Copyright © 1998 - 2018 StockSelector.com. All rights reserved.